US ‘eroding’ lead in rare diseases a matter of national security: Report

Summary

A Congressional advisory panel recommends the U.S. government adopt supportive policies for rare disease drug development, including FDA platform designation and novel trial designs for small patient populations, citing national security concerns over eroding U.S. leadership.